{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.6","upperLimit":"46.5","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The percentage of participants with at least 1 zoledronate dose reduction during the study was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Zoledronate"}],"paramType":"NUMBER","populationDescription":"ITT Population; only the Zoledronate arm was included.","reportingStatus":"POSTED","timeFrame":"From Baseline to end of study (up to Week 96)","title":"Percentage of Participants With Zoledronate Dose Reduction","type":"SECONDARY","unitOfMeasure":"percentage of participants"}